구조모아 (StructureMoa)항암 chemical structure spider web
방문타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 3개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | axicabtagene ciloleucel (Yescarta, axi-cel) Kite / Gilead·CD19 68 trials·t½ CAR T expansion peak ~7–14 days post-infusion; persistence months in responders | ||
|---|---|---|---|
Overview Program | Yescarta (axicabtagene ciloleucel) | Kymriah (tisagenlecleucel) | autologous CD19-directed chimeric antigen receptor (CAR) T-cells |
Overview Company | Kite / Gilead | Novartis | AstraZeneca |
Overview Modality | CGT | CGT | CGT |
Overview Target | CD19 | CD19 | CD19 |
Overview Indication | LBCL, FL | ALL, DLBCL, FL | Relapsed Non Hodgkin Lymphoma; Relapsed Adult ALL |
Overview Phase | APPROVED | APPROVED | PHASE_2 |
Overview Status | APPROVED | APPROVED | RECRUITING |
Overview Content status | Curated Core | Curated Core | Standard Database |
Overview Data Confidence | Data Confidence · High | Data Confidence · High | Data Confidence · Medium |
Overview Development Signal | Development Signal · Established | Development Signal · Established | Development Signal · Emerging |
Overview Approval status | FDA approved | FDA approved | Investigational |
Positioning Key differentiator | Rapid manufacturing, CD28 signaling | 4-1BB persistence profile | — |
Positioning Known limitation | CD19 antigen loss, T-cell exhaustion, and hostile tumor microenvironment. | downregulation of naïve T-cell-associated genes (SELL and CD28) | — |
Positioning Development positioning | First mover in CD19 CAR-T LBCL | — | — |
Technology Vector | Retrovirus | Lentivirus | AAV) but is clinically still in an early developmental stage |
MoA Mechanism | Autologous T cells transduced with a retroviral vector encoding an anti-CD19 CAR (scFv + CD28 + CD3ζ). CAR T cells expand in vivo, recognize CD19 on B cells, and mediate cytotoxic killing. | Autologous T cells transduced with lentiviral vector encoding CD19-specific CAR with 4-1BB and CD3ζ signaling domains. Engages CD19+ B cells leading to proliferation and cytotoxicity. | CAR T-cell product type, and higher day 0 C-reactive protein were independently associated with lower odds of 72-hour SNI |
MoA Biomarker | CD19 expression on lymphoma cells; CAR T expansion in blood. | CD19; measurable residual disease in ALL. | biomarkers such as body composition metrics |
PK/PD Half-life | CAR T expansion peak ~7–14 days post-infusion; persistence months in responders | — | — |
PK/PD Species | resistance, toxicity, and precision strategies., CAR T copy number in blood, B-cell aplasia | NHP, CAR T transgene persistence, B-cell aplasia | Dog, Human |
PK/PD Animal (cat.) | Unknown | NHP, In vitro | Human, Dog, In vitro |
PK/PD Experiment | pharmacodynamic | pharmacodynamic | PD |
Toxicology Species | resistance, toxicity, and precision strategies. | NHP, Mouse | Dog, Human |
Toxicology Animal (cat.) | Unknown | Human | Human, Dog, In vitro |
Toxicology Major finding | CRS, ICANS, cytopenias | CRS and neurological events; hypogammaglobulinemia from B-cell aplasia. | Clinical Pharmacology of Lisocabtagene Maraleucel in B-cell Malignancies.. Chimeric antigen receptor (CAR) T-cell therapies represent a distinct therapeutic modality whose clinical activity is governed by in vivo cellular kinetics. Lisocabtagene maraleucel (liso-cel) is an autologous CD19-directed, 4-1BB CAR T-cell product in which in vivo expansion plays an important role in clinical pharmacology… |
Toxicology CRS | Grade ≥3 ~13% | CRS ~58–79% in ALL; Grade ≥3 CRS managed with tocilizumab per protocol | Reported |
Clinical Safety signal | CRS, ICANS, cytopenias | CRS and neurological events; hypogammaglobulinemia from B-cell aplasia. | Clinical Pharmacology of Lisocabtagene Maraleucel in B-cell Malignancies.. Chimeric antigen receptor (CAR) T-cell therapies represent a distinct therapeutic modality whose clinical activity is governed by in vivo cellular kinetics. Lisocabtagene maraleucel (liso-cel) is an autologous CD19-directed, 4-1BB CAR T-cell product in which in vivo expansion plays an important role in clinical pharmacology… |
Clinical Selected reported efficacy | ORR 92% | — | ORR 77.3% |
Clinical Reported ORR | 94% | — | 77.3% |
Clinical Reported PFS | 40.2 | — | — |
Clinical Reported OS | NA | 0 | 88 |
Clinical Result source | ClinicalTrials.gov NCT03105336 | ClinicalTrials.gov NCT04225676 | ClinicalTrials.gov NCT03642626 |
Clinical Program phase | APPROVED | APPROVED | PHASE_2 |
Clinical Trial activity | No active/completed counts | No active/completed counts | No active/completed counts |
Clinical Trial ref | NCT03105336 | NCT04225676 | NCT03642626 |
타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 3개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | axicabtagene ciloleucel (Yescarta, axi-cel) Kite / Gilead·CD19 68 trials·t½ CAR T expansion peak ~7–14 days post-infusion; persistence months in responders | ||
|---|---|---|---|
Overview Program | Yescarta (axicabtagene ciloleucel) | Kymriah (tisagenlecleucel) | autologous CD19-directed chimeric antigen receptor (CAR) T-cells |
Overview Company | Kite / Gilead | Novartis | AstraZeneca |
Overview Modality | CGT | CGT | CGT |
Overview Target | CD19 | CD19 | CD19 |
Overview Indication | LBCL, FL | ALL, DLBCL, FL | Relapsed Non Hodgkin Lymphoma; Relapsed Adult ALL |
Overview Phase | APPROVED | APPROVED | PHASE_2 |
Overview Status | APPROVED | APPROVED | RECRUITING |
Overview Content status | Curated Core | Curated Core | Standard Database |
Overview Data Confidence | Data Confidence · High | Data Confidence · High | Data Confidence · Medium |
Overview Development Signal | Development Signal · Established | Development Signal · Established | Development Signal · Emerging |
Overview Approval status | FDA approved | FDA approved | Investigational |
Positioning Key differentiator | Rapid manufacturing, CD28 signaling | 4-1BB persistence profile | — |
Positioning Known limitation | CD19 antigen loss, T-cell exhaustion, and hostile tumor microenvironment. | downregulation of naïve T-cell-associated genes (SELL and CD28) | — |
Positioning Development positioning | First mover in CD19 CAR-T LBCL | — | — |
Technology Vector | Retrovirus | Lentivirus | AAV) but is clinically still in an early developmental stage |
MoA Mechanism | Autologous T cells transduced with a retroviral vector encoding an anti-CD19 CAR (scFv + CD28 + CD3ζ). CAR T cells expand in vivo, recognize CD19 on B cells, and mediate cytotoxic killing. | Autologous T cells transduced with lentiviral vector encoding CD19-specific CAR with 4-1BB and CD3ζ signaling domains. Engages CD19+ B cells leading to proliferation and cytotoxicity. | CAR T-cell product type, and higher day 0 C-reactive protein were independently associated with lower odds of 72-hour SNI |
MoA Biomarker | CD19 expression on lymphoma cells; CAR T expansion in blood. | CD19; measurable residual disease in ALL. | biomarkers such as body composition metrics |
PK/PD Half-life | CAR T expansion peak ~7–14 days post-infusion; persistence months in responders | — | — |
PK/PD Species | resistance, toxicity, and precision strategies., CAR T copy number in blood, B-cell aplasia | NHP, CAR T transgene persistence, B-cell aplasia | Dog, Human |
PK/PD Animal (cat.) | Unknown | NHP, In vitro | Human, Dog, In vitro |
PK/PD Experiment | pharmacodynamic | pharmacodynamic | PD |
Toxicology Species | resistance, toxicity, and precision strategies. | NHP, Mouse | Dog, Human |
Toxicology Animal (cat.) | Unknown | Human | Human, Dog, In vitro |
Toxicology Major finding | CRS, ICANS, cytopenias | CRS and neurological events; hypogammaglobulinemia from B-cell aplasia. | Clinical Pharmacology of Lisocabtagene Maraleucel in B-cell Malignancies.. Chimeric antigen receptor (CAR) T-cell therapies represent a distinct therapeutic modality whose clinical activity is governed by in vivo cellular kinetics. Lisocabtagene maraleucel (liso-cel) is an autologous CD19-directed, 4-1BB CAR T-cell product in which in vivo expansion plays an important role in clinical pharmacology… |
Toxicology CRS | Grade ≥3 ~13% | CRS ~58–79% in ALL; Grade ≥3 CRS managed with tocilizumab per protocol | Reported |
Clinical Safety signal | CRS, ICANS, cytopenias | CRS and neurological events; hypogammaglobulinemia from B-cell aplasia. | Clinical Pharmacology of Lisocabtagene Maraleucel in B-cell Malignancies.. Chimeric antigen receptor (CAR) T-cell therapies represent a distinct therapeutic modality whose clinical activity is governed by in vivo cellular kinetics. Lisocabtagene maraleucel (liso-cel) is an autologous CD19-directed, 4-1BB CAR T-cell product in which in vivo expansion plays an important role in clinical pharmacology… |
Clinical Selected reported efficacy | ORR 92% | — | ORR 77.3% |
Clinical Reported ORR | 94% | — | 77.3% |
Clinical Reported PFS | 40.2 | — | — |
Clinical Reported OS | NA | 0 | 88 |
Clinical Result source | ClinicalTrials.gov NCT03105336 | ClinicalTrials.gov NCT04225676 | ClinicalTrials.gov NCT03642626 |
Clinical Program phase | APPROVED | APPROVED | PHASE_2 |
Clinical Trial activity | No active/completed counts | No active/completed counts | No active/completed counts |
Clinical Trial ref | NCT03105336 | NCT04225676 | NCT03642626 |
추천 비교
추천 비교